1887
Preview this article:
Zoom in
Zoomout

Multidrug-resistant pulmonary infection in cystic fibrosis – what does ‘resistant’ mean?, Page 1 of 1

| /docserver/preview/fulltext/jmm/55/12/1615-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46884-0
2006-12-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/12/1615.html?itemId=/content/journal/jmm/10.1099/jmm.0.46884-0&mimeType=html&fmt=ahah

References

  1. Aaron, S. S. D., Vandemheen, K. L., Ferris, W. & 20 other authors ( 2005; ). Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multi-resistant bacteria. Lancet 366, 463–471.[CrossRef]
    [Google Scholar]
  2. Burns, J. L., Van Dalfsen, J. M., Shawar, R. M. & 7 other authors ( 1999; ). Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179, 1190–1196.[CrossRef]
    [Google Scholar]
  3. Burns, J. L., Saimon, L., Whittier, S., Krzewinski, J., Liu, Z., Larone, D., Marshall, S. A. & Jones, R. N. ( 2001; ). Comparison of two commercial systems (Vitek and MicroScan WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 39, 257–260.[CrossRef]
    [Google Scholar]
  4. Drenkard, E. & Ausubel, F. M. ( 2002; ). Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416, 740–743.[CrossRef]
    [Google Scholar]
  5. Falagas, M. E., Koletsi, P. K. & Bliziotis, I. A. ( 2006; ). The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 55, 1619–1629.[CrossRef]
    [Google Scholar]
  6. Foweraker, J. E., Laughton, C. R., Brown, D. F. J. & Bilton, D. ( 2005; ). Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 55, 921–927.[CrossRef]
    [Google Scholar]
  7. Fyfe, J. A. M. & Govan, J. R. W. ( 1984; ). Chromosomal loci associated with antibiotic hypersensitivity in pulmonary isolates of Pseudomonas aeruginosa. J Gen Microbiol 130, 825–834.
    [Google Scholar]
  8. Govan, J. R. W. ( 2002; ). Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 1, S203–S208.[CrossRef]
    [Google Scholar]
  9. Govan, J. R. W. & Deretic, V. ( 1996; ). Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60, 539–574.
    [Google Scholar]
  10. Hill, D., Rose, B., Pajkos, A. & 8 other authors ( 2005; ). Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic and biofilm conditions. J Clin Microbiol 43, 5085–5090.[CrossRef]
    [Google Scholar]
  11. Lam, J., Chan, R., Lam, K. & Costerton, J. W. ( 1980; ). Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 28, 546–556.
    [Google Scholar]
  12. MacGowan, A. P. & Wise, R. ( 2001; ). Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 48, 17–28.[CrossRef]
    [Google Scholar]
  13. McGowan, J. E. ( 2006; ). Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 34, S29–S37.[CrossRef]
    [Google Scholar]
  14. Morosini, M. I., Garcia-Castillo, M., Loza, E., Perez-Vasquez, M., Baquero, F. & Canton, R. ( 2005; ). Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 43, 4480–4485.[CrossRef]
    [Google Scholar]
  15. Moskowitz, S. M., Foster, J. M., Emmerson, J. & Burns, J. L. ( 2004; ). Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42, 1915–1922.[CrossRef]
    [Google Scholar]
  16. Moskowitz, S. M., Foster, J. M., Emerson, J. C., Gibson, R. L. & Burns, J. L. ( 2005; ). Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56, 879–886.[CrossRef]
    [Google Scholar]
  17. Sader, H., Fritsche, T. R. & Jones, R. N. ( 2006; ). Accuracy of three automated systems (MicroScan Walkaway, VITEK, and VITEK2) for susceptibility testing of Pseudomonas aeruginosa against five broad spectrum β-lactam agents. J Clin Microbiol 44, 1101–1104.[CrossRef]
    [Google Scholar]
  18. Saiman, L., Burns, J. L., Whittier, S., Krzewinski, J., Marshall, S. A. & Jones, R. N. ( 1999; ). Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 37, 2987–2991.
    [Google Scholar]
  19. Smith, A. L, Fiel, S. B., Mayer-Hamblett, N., Ramsey, B. & Burns, J. L. ( 2003; ). Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Chest 123, 1495–1502.[CrossRef]
    [Google Scholar]
  20. Smyth, A. ( 2005; ). Multiresistant pulmonary infection in cystic fibrosis – prevention is better than cure. Lancet 366, 433–435.[CrossRef]
    [Google Scholar]
  21. Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G. & Edwards, J. E. ( 2004; ). Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38, 1279–1286.[CrossRef]
    [Google Scholar]
  22. Stewart, P. S. & Costerton, J. W. ( 2001; ). Antibiotic resistance of bacteria in biofilms. Lancet 358, 135–138.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46884-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error